We show that peptide fragments of the dihydropyridine receptor II-III loop alter cardiac RyR (ryanodine receptor) channel activity in a cytoplasmic Ca 2+ -dependent manner. The peptides were A C (Thr-793-Ala-812 of the cardiac dihydropyridine receptor), A S (Thr-671-Leu-690 of the skeletal dihydropyridine receptor), and a modified A S peptide [A S (D-R18) (D-R18) is not influenced by [Ca 2+ ] and (ii) that peptide A C adopts a helical structure, particularly in the region containing positively charged residues. This is the first report of specific functional interactions between dihydropyridine receptor A region peptides and cardiac RyR ion channels in lipid bilayers.
INTRODUCTION
The RyR (ryanodine receptor) Ca 2+ -release channel is located in the SR (sarcoplasmic reticulum) of striated muscle fibres. The Ca 2+ required for muscle contraction is released from Ca 2+ stores in the terminal cisternae of the SR through RyR channels. During EC (excitation-contraction) coupling, the cardiac RyR is activated by a Ca 2+ influx through L-type Ca 2+ channels [DHPRs (dihydropyridine receptors)], via Ca 2+ -induced Ca 2+ release. In contrast in skeletal muscle, RyR1 is thought to be activated during EC coupling by a protein-protein interaction with DHPR, not by Ca 2+ -induced Ca 2+ release. The II-III loop between the second and third repeats of the DHPR, with the skeletal sequence between Leu-720 and Leu-764, is required for skeletal-type EC coupling, which is independent of Ca 2+ influx through the DHPR [1] [2] [3] . Because of its central role in EC coupling, the RyR is a useful pharmacological target for modulating muscle contraction and RyR-active compounds such as caffeine, ryanodine, dantrolene and cADP ribose are frequently used in this capacity [4] . Peptides derived from the A region (residues Thr-671-Leu-690) of the II-III loop of the skeletal muscle DHPR provide a new class of compounds that interact with RyR channels. These peptides (at 1 µM) enter the pore from the cytoplasm and block skeletal RyR channels at positive membrane potentials, when current flows from the cytoplasmic to the luminal side of the channel [5, 6] . The peptides are effective activators of skeletal muscle RyRs at lower concentrations (1-100 nM) and have been used in this capacity to Abbreviations used: RyR, ryanodine receptor; SR, sarcoplasmic reticulum; EC, excitation-contraction; DHPR, dihydropyridine receptor; BAPTA, bis-(oaminophenoxy)ethane-N,N,N ,N -tetra-acetic acid; NOESY, nuclear Overhauser enhancement spectroscopy. 1 To whom correspondence should be addressed, at PO Box 334, Canberra, ACT 2601, Australia (e-mail angela.dulhunty@anu.edu.au).
probe skeletal muscle RyR activity [7] [8] [9] [10] . The same peptides have been found to be ineffective in activating cardiac RyRs [11, 12] . This inability to activate cardiac RyRs is surprising for several reasons. Firstly, a scorpion toxin (imperatoxin A) that is thought to bind to the same site as the skeletal A peptide acts on both cardiac and skeletal RyRs [6, [13] [14] [15] . Secondly, the recombinant skeletal DHPR II-III loop binds to cardiac RyRs in a two-hybrid system [16] and the skeletal A peptide binds to cardiac RyRs in surface plasmon resonance [17] . Since these observations show that skeletal DHPR fragments bind to cardiac RyRs, we have further investigated the functional effects of the skeletal DHPR A fragments on cardiac RyR channels. The actions of the cardiac A fragment have also been examined, since the C-terminal 10 residues of this peptide reduce Ca 2+ spark frequency in cardiac myocytes [18] .
We find that the A fragments of both skeletal and cardiac DHPR, as well as modified skeletal A fragments, alter cardiac RyR activity in a [Ca 2+ ]-dependent manner. The peptides activate cardiac RyR channels when the cytoplasmic [Ca 2+ ] is sub-activating (100 nM), but inhibit channels that are activated by 10-100 µM Ca 2+ . Both these effects of the peptides are voltage-independent. The inhibition of the channel at activating Ca 2+ is distinctly different from a voltage-dependent block seen only at positive potentials and only with the native skeletal A fragment. The cardiac DHPR A fragment depressed Ca 2+ -induced Ca 2+ release from cardiac SR, whereas the skeletal DHPR A fragments enhanced both resting and Ca 2+ -induced Ca 2+ release. The activating effects of the A peptides [12] and (ii) it is most prominent in enhancing Ca 2+ -induced Ca 2+ release from cardiac SR, but only resting Ca 2+ has been examined previously. We conclude that these DHPR fragments corresponding to the skeletal and cardiac DHPR A region bind to the cardiac RyR, alter its activity under appropriate conditions, and can therefore be used as probes for cardiac as well as skeletal RyR function.
EXPERIMENTAL

Materials
The following peptides were synthesized [5, 19, 20] 
Isolation of SR vesicles
The techniques were modified from Chamberlain and Fleischer [21] as described in [22] . Crude microsmal vesicles were suspended in buffer containing 290 mM sucrose, 10 mM imidazole (pH 6.9 with HCl), 0.5 mM dithiothreitol, 3 mM sodium azide and 650 mM KCl, plus protease inhibitors (2.2 µM leupeptin, 1 µM pepstatin A, 1 mM benzamidine and 0.5 mM PMSF in DMSO). The crude vesicles were snap-frozen and stored either in liquid N 2 or at − 70 dissolved at 2 mM in the cis bilayer solution (above). NMR spectroscopy was then performed as described previously [19, 20] .
Statistics
The significance of differences between values was tested using a Students t test, either one-or two-tailed, for independent or paired data as appropriate or by the non-parametric Sign test [23] . Differences were considered significant when P 0.05. Data are shown as means + − 1 × S.E.M.
RESULTS
Peptides were added to the cis solution bathing the cytoplasmic side of native cardiac RyR channels. The channels were identified as RyRs by their Cs + conductance of approx. 250 pS (with 1 mM trans Ca 2+ ) and their block by 30 µM Ruthenium Red. 
Effects of the cardiac peptide, A C , on cardiac RyR channels
MgATP was used to better reproduce in vivo conditions and its addition resulted in increased activity at both cis [Ca 2+ ]s (Table 1) as previously reported [24] . Peptide A C increased cardiac RyR activity when cis [Ca 2+ ] was 100 nM (Figure 1 ). Washout of 100 µM A C and MgATP led to a fall in activity, due to dilution of ATP and peptide. Activity after washout was greater than the initial activity ( Table 2 ), indicating that the peptide, although diluted, remained at an activating concentration and was effective in the virtual absence of MgATP. Reversible activation was seen when a lower concentration of 100 nM peptide A C was used ( Figure 1B) .
Activation by peptide A C was caused by a reduction in the time that the channel was closed (Figure 2 ). The similar changes in mean current and open probability show that the data was not substantially biased by exclusion of small-conductance openings (open probability analysis) or inclusion of multiple channel activity (mean current analysis). In contrast to activation with 100 nM cis Ca 2+ , reversible inhibition was seen when when peptide A C was added to channels activated by cis [Ca 2+ ] of 10 or 100 µM ( Figure 3 ). Perfusion of 100 µM peptide A C from the cis chamber (with dilution to approx. 30 nM) was accompanied by some recovery of activity ( Figure 3 ). The reduction in activity (mean current and open probability) was due to a decrease in the duration of the channel opening (Figure 4) . The [Ca 2+ ]-dependence of the effect of peptide A C ( Figure 4E) shows that activation at 100 nM Ca 2+ declines with 1 µM Ca 2+ and that the effect of the peptide becomes inhibitory at 10 and 100 µM Ca 2+ . The inhibition of single Ca 2+ -activated channels was reflected in the effect of peptide A C on Ca 2+ release from cardiac SR vesicles. The peptide had little effect on resting Ca 2+ release, but reduced the rate of Ca 2+ -induced Ca 2+ release ( Figure 5 ).
The effects of the native and modified skeletal peptide, A S , on cardiac RyR channels
MgATP was omitted in experiments with peptide A S because the peptide failed to activate pig skeletal RyRs in the presence of ATP [7] . However, since the peptide also interacted with channels in SR vesicles in the presence of MgATP (see below), the effects on the cardiac RyR were not ATP-dependent. Peptide A S caused a reversible increase in channel activity when cis [Ca 2+ ] was 100 nM. Channel activation was greater at − 40 mV than at + 40 mV and there were more channel openings to submaximal conductance levels with 1 µM peptide A S at + 40 mV ( Figure 6 ). The subconductance activity has been described with skeletal RyRs and attributed to pore block following binding of the basic peptide A S to low-affinity acidic sites, located in the pore [5] . Average data showed a monophasic increase in activity at − 40 mV, but biphasic increase at + 40 mV, because higher concentrations of peptide blocked the channel ( Figures 7A and 7B,  ᭹) . The increase in activity was caused by a substantial decrease in closed times ( Figure 7D ).
The ability of the peptide A S to activate the RyR channel was substantially reduced with 100 cis µM Ca 2+ . Although pore block at + 40 mV was stronger at the higher cis [Ca 2+ ], activity at − 40 mV was not significantly different from control (Figure 7, ᭺) . ] was stronger than that with peptide A C or peptide A S , but, as with the other two peptides, was due to a decrease in channel closed times ( Figures 8A-8D, ᭹) . Conversely, voltage-independent inhibition in the presence of 100 µM cis [Ca 2+ ] was caused by an abbreviation of the open times ( Figures 8A-8D, ᭺) .
Voltage-dependent block of activity was not seen for A S (D-R18) with 100 nM Ca 2+ , and, if present with 100 µM Ca 2+ , was masked by inhibition. The effects of A S (D-R18) on the cardiac RyR were more strongly Ca 2+ -dependent than the effects of either peptide A S or A C , with activation being substantially reduced at a cis [Ca 2+ ] of only 500 nM (compare Figure 8E with Figures 4E and 7E above) .
Actions of peptides A S (D-R18), A C and A S are not additive
To examine the possibility that the cardiac and skeletal A peptides were acting at one site, channels were first exposed to 1 µM A S (D-R18), then 1 µM A C was added and finally 1 µM A S ( Figure 8F ). There was no additive activation by the peptides with either 100 or 500 nM cis Ca There is an increase in submaximal conductance activity (arrows) in the presence of A S , seen predominantly at + 40 mV. The record in (C) shows 300 ms of activity with 1 µM peptide A S at + 40 mV with maintained openings to at least three different submaximal conductance levels (arrows). o and c are defined in the legend to Figure 1. sequence) did not activate the cardiac RyR with 100 nM cis Ca 2+ (Table 3) . A S S caused a voltage-dependent block in channel activity at + 40 mV. The scrambled peptide caused a similar block of skeletal RyR channels, consistent with the non-specific nature of this action [5] .
Peptides A S and A S (D-R18) enhance Ca 2+ -induced Ca 2+ release from cardiac SR
The A S peptides caused a small increase in resting Ca 2+ release from cardiac SR, and a substantial increase in both caffeine and Ca 2+ -induced Ca 2+ release ( Figure 9B ). Resting Ca 2+ release with vehicle alone had a small negative slope, because release is expressed as the rate of release after peptide/vehicle addition (Figure 9A, slope b) minus the preceding rate with thapsigargin ( Figure 9A, slope a) . Two additional mutant A S peptides, A S 2 (Ser-687 → Ala) and A S 2(D-R18) (Ser-687 → Ala; with the D isomer of Arg-688), activate skeletal RyR1 and enhance resting Ca 2+ release from skeletal SR with an efficiency of A S < A S 2 < A S (D-R18) < A S 2(D-R18) [6, 19] . Differential activation of cardiac RyRs was seen in resting Ca 2+ release, which tended to be greater with A S (D-R18) and A S 2(D-R18) than with the other peptides ( Figure 9 ). The peptides each had a similar action on activated Ca 2+ release, possibly because RyR channels were close to maximally activated under these conditions. Peptide A S 2(D-R18) had no effect on the rate of Ca 2+ uptake by cardiac SR ( Figure 9C ). Similar results were obtained with peptide A S (n = 5) and peptide A S 2 (n = 5). 
Ca
2+ -release pathways from cardiac SR
Some Ca 2+ release evoked by the peptides may have occurred through a RyR-indpendent pathway such as the SR Ca 2+ -ATPase [25, 26] . This seemed unlikely since thapsigargin was present and is likely to inhibit Ca 2+ back flux. Further, resting Ca 2+ release was abolished by Ruthenium Red added (i) 3 min after the peptide or (ii) 3 min before the peptide (Table 4) .
Similarly 
(D-R18).
The amide region of a series of NOESY (nuclear Overhauser enhancement spectroscopy) spectra are shown in Figure 10 . The off-peak diagonals denote amide protons which are close in space to other amide protons (< 5 Å), indicating that a portion of A S (D-R18) adopts a helical structure, as reported previously [15] . The number and location of the cross-peaks (Figure 10 , arrows) were identical at the different Ca 2+ concentrations and in the absence of added Ca 2+ , suggesting that the structure and overall molecular environment of the peptides was similar. The spectra in Figure 10 , obtained with the bilayer solution as the peptide vehicle, lacked clarity when compared with spectra obtained with H 2 O/ 2 H 2 O (Figure 11 ) because of the complex ionic conditions.
Comparison of the NOESY spectra of peptides A C and A S
The activity of the A S peptides on skeletal RyRs depends on their α helical structure [15] . Therefore the parallel Ca 2+ -dependent changes in cardiac RyR activity with the A C and A S peptides suggest that the peptides may have structural homology. NOESY spectra show the presence of strong cross-peaks, indicating the presence of α helical regions in both peptides (Figure 11 ). The first five residues of peptide A C are similar to the A S peptide but the rest of the sequence is different, particularly the stretch of glutamate residues located towards the middle of the peptide (see the Experimental section). Nevertheless, the C-terminal half of the peptide contains five basic amino acid residues, and connectivities between the cross-peaks in the NOESY spectrum for A C (Figure 11) show that these adopt a mostly α-helical conformation. The sequence and conformation of the A S peptides are important for receptor recognition [20] . Therefore, the ability of the basic residues in peptide A C to adopt an α-helical conformation may explain the ability of the peptide to interact with the cardiac RyR in a similar manner to the A S peptides.
DISCUSSION
The results show that peptide fragments with sequences corresponding to the A region of the II-III loop of the cardiac and skeletal DHPR alter the activity of native cardiac RyR channels in a Ca 2+ -dependent manner and alter Ca 2+ release from cardiac SR. NMR studies show structural similarities between the A fragments of the cardiac and skeletal DHPR. The results are consistent with observations that parts of the cardiac and skeletal DHPR bind to the cardiac RyR. Specific functional changes in single cardiac RyR channel activity, induced by binding of fragments of the DHPR, have not been previously reported.
Why have interactions between the skeletal DHPR II-III loop fragments and cardiac RyR channels not been reported previously?
Surface plasmon resonance and two hybrid studies [16, 17] indicate that the skeletal DHPR can bind to the cardiac RyR complex. The binding of skeletal II-III loop fragments to the cardiac RyR is not surprising since there is 72 % homology between cardiac and skeletal RyRs [27] and 66 % homology between cardiac and skeletal DHPRs [28] . In addition, sequences of two skeletal RyR regions that associate with the skeletal DHPR [16, 29] are similar in the cardiac RyR. What is surprising is that there are no reports of the functional consequences of this interaction. The effects on Ca 2+ release from cardiac SR may not have been seen because the peptides alter this release only (i) during Ca 2+ -induced Ca 2+ release and (ii) in the presence of thapsigargin. Previous Ca 2+ release studies [8, 11] were not done under these conditions. The effects on single channel activity may not have been seen because purified cardiac RyR channels were examined at activating cis [Ca 2+ ] [12] . The use of higher cis [Ca 2+ ] would have reduced the ability of the peptides to enhance channel activity. Furthermore, purification may have altered the ability of channels to respond to DHPR fragments, by either removing an associated protein or by modifying the channel. Proteins that remain associated with the RyR in bilayers include triadin/junctin and calsequestrin [30] as well as FK506-binding proteins, Ca 2+ /calmodulin kinase II and protein kinase A [31] [32] [33] [34] . Therefore some of the interactions described here may depend on, or be modulated by, an associated protein. Indeed, the action of calsequestrin on the RyR is mediated by triadin and junctin [30] , while interactions between the skeletal DHPR II-III loop and RyR require FKBP12 [5, 35, 36] .
Can different isoforms of the DHPR and RyR interact?
The results suggest that both the skeletal and cardiac DHPRs have the potential to physically interact with cardiac RyRs. Interactions between the C region of the cardiac DHPR II-III loop and skeletal RyR have been reported [6] as has co-immunoprecipitation of the cardiac DHPR and skeletal RyR [37] . If the cardiac DHPR can associate with the skeletal RyR, then why is skeletal EC coupling abolished in dysgenic myocytes transfected with cardiac DHPR [2, 38] ? It is likely that skeletal EC coupling depends on correct targeting of sufficient numbers of DHPRs into tetrads located directly opposite RyRs [39] . Similarly the skeletal RyR may be a co-requisite for correct targeting of the DHPR into tetrads, and for appropriate transmission of the EC coupling signal through the RyR to the channel gating mechanism [40] .
Is there a physical interaction between the DHPR and RyR in the heart?
The A region of the skeletal DHPR appears not to be directly involved in skeletal EC coupling [1] [2] [3] , and its role in the interaction between the skeletal DHPR and RyR remains uncertain [3] . Nevertheless the present results revive the possibility that there is a physical association between the DHPR and RyR in cardiac muscle [18, 41] . DHPRs do not form tetrads in the heart [42] and the DHPR/RyR ratio is lower than in skeletal muscle [43] , therefore only a few RyRs could be physically associated with DHPRs. Depolarization-induced conformational coupling in the heart is supported by some studies [44] , but not others [45] and not generally thought to contribute to EC coupling [46] . However, an association between the proteins could allow the DHPR to modulate EC coupling and/or resting Ca 2+ release under some conditions.
Voltage-dependent and -independent interactions between the peptides and the cardiac RyR
The different actions of the peptides are likely to reflect peptide binding to at least two different sites on the RyR complex. The voltage-dependent (Ca 2+ -independent) block by A S is attributed to an interaction between positively charged residues in the peptide and negatively charged residues in the pore [5] and is observed with other basic peptides which also block K + channels [47] . In contrast the voltage-independent effects are due to peptide binding to a region that is not influenced by membrane field. It is likely that voltage-independent effects were induced by peptides A S (D-R18), A C and A S binding to the same site on the RyR given their structural similarity, their similar Ca 2+ dependence and the nonadditive nature of their effects. Since the peptide structure was not influenced by [Ca 2+ ], either (i) the RyR's response to peptide binding to one site is Ca 2+ -dependent, or (ii) different binding sites are available at sub-activating and activating [Ca 2+ ]. The experiments did not distinguish between these possibilities.
It was not surprising that voltage-dependent block was seen only with peptide A S because the low positive charge density on peptide A C [48] would reduce its capacity to interact with acidic pore residues, while the structured nature of A S (D-R18) [15] would prevent it from blocking the pore (since the A peptides block with lower efficacy as peptide structure increases [19] 1 µM. However Ca 2+ release in the presence of 20 µM Ca 2+ was depressed.
The effects of the skeletal A S peptides were also similar in the bilayer and Ca 2+ -release experiments in that activation was seen in both cases. However, in this case, although the peptides enhanced channel activity less at higher Ca 2+ concentrations, Ca 2+ -induced Ca 2+ release was potentiated more than resting Ca 2+ release. Thus the Ca 2+ concentration dependence of the A peptide's action was different in the bilayer and Ca 2+ -release experiments. Since the transition between activation and inhibition occurred at approx. 10 µM cis Ca 2+ , only a small shift in the Ca 2+ -dependence could explain the results.
Although skeletal and cardiac RyR channels in bilayers are similarly sensitive to the A S peptides, Ca 2+ release from cardiac SR is less sensitive to the peptides than release from skeletal SR [5] . It is possible that peptide concentrations could not be increased sufficiently to enhance Ca 2+ release, since more peptide is required to induce Ca 2+ release than to activate channels in bilayers [5, 35, 49] . The properties of channels in bilayers may differ from those in vesicles, perhaps because of the infiltration of non-native lipids in the bilayer system or because of the different ionic conditions or the presence of antipyralazo in the Ca 2+ release experiments. However, since peptides A S and A S (D-R18) increase resting Ca 2+ efflux from skeletal SR under our conditions [5, 15] , cardiac channels appear to be more sensitive to differences between the techniques.
A peptide corresponding to the C-terminal 10 residues of A C reduces Ca 2+ spark frequency in cardiac myocytes [18] , whereas the full peptide A C enhanced cardiac RyRs in bilayers with a resting [Ca 2+ ] of 100 nM. The different-length peptides may have slightly different actions on the RyR. However, the results can be explained if the [Ca 2+ ] near the RyR channel at the time of spark initiation is > 100 nM. The [Ca 2+ ] near the channel is greater than in the bulk solution, because of Ca 2+ leak through the pore from the luminal store or Ca 2+ entry through nearby L-type Ca 2+ channels [50, 51] . A Ca 2+ spark occurs when local increases in [Ca 2+ ] initiate Ca 2+ -induced Ca 2+ release. Thus, with Ca 2+ near the pore well in excess of 100 nM before spark initiation, we would predict that peptide A C would reduce the probability of the RyR opening and spark generation.
In conclusion, we show functional interactions between the cardiac RyR and the A region of both the cardiac and skeletal DHPR. This study supports the possibility that DHPR can become physically coupled (either directly or through associated proteins) to cardiac RyRs in the myocardium. Such coupling is clearly not the mechanism for cardiac EC coupling, but could have other functional implications which require further investigation. The results show that the cardiac and skeletal A region peptides can be used as probes for cardiac and skeletal RyR channel activity.
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